XSpray Pharma AB (XSPRAY) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.058x

Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has a cash flow conversion efficiency ratio of -0.058x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-36.95 Million ≈ $-3.98 Million USD) by net assets (Skr637.50 Million ≈ $68.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XSpray Pharma AB stock valuation for the company's overall valuation and market capitalisation.

XSpray Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how XSpray Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

XSpray Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of XSpray Pharma AB ranked by their cash flow conversion efficiency. Explore XSpray Pharma AB (XSPRAY) cash flow quality to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Lion Chemtech Co. Ltd KQ:171120	0.012x
Akin Tekstil AS IS:ATEKS	0.001x
Sequana Medical NV BR:SEQUA	0.254x
TAPEX INC KO:055490	0.003x
Nuveen New York Select Tax-Free Income Portfolio NYSE:NXN	N/A
Intellicheck Mobilisa Inc NASDAQ:IDN	0.080x
Timberwell Bhd KLSE:7854	0.007x
Nice Information & Telecommunication Inc KQ:036800	0.088x

Annual Cash Flow Conversion Efficiency for XSpray Pharma AB (2015–2025)

The table below shows the annual cash flow conversion efficiency of XSpray Pharma AB from 2015 to 2025. View XSPRAY stock price for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr604.65 Million ≈ $65.07 Million	Skr-193.16 Million ≈ $-20.79 Million	-0.319x	+10.48%
2024-12-31	Skr623.10 Million ≈ $67.06 Million	Skr-222.37 Million ≈ $-23.93 Million	-0.357x	-21.74%
2023-12-31	Skr693.41 Million ≈ $74.62 Million	Skr-203.28 Million ≈ $-21.88 Million	-0.293x	-47.94%
2022-12-31	Skr556.02 Million ≈ $59.84 Million	Skr-110.18 Million ≈ $-11.86 Million	-0.198x	-127.22%
2021-12-31	Skr591.75 Million ≈ $63.68 Million	Skr-51.61 Million ≈ $-5.55 Million	-0.087x	-6.31%
2020-12-31	Skr582.59 Million ≈ $62.70 Million	Skr-47.79 Million ≈ $-5.14 Million	-0.082x	+10.46%
2019-12-31	Skr373.71 Million ≈ $40.22 Million	Skr-34.24 Million ≈ $-3.68 Million	-0.092x	-55.76%
2018-12-31	Skr301.72 Million ≈ $32.47 Million	Skr-17.75 Million ≈ $-1.91 Million	-0.059x	+17.07%
2017-12-31	Skr155.66 Million ≈ $16.75 Million	Skr-11.04 Million ≈ $-1.19 Million	-0.071x	-89.00%
2016-12-31	Skr46.47 Million ≈ $5.00 Million	Skr-1.74 Million ≈ $-187.68K	-0.038x	+96.45%
2015-12-31	Skr12.26 Million ≈ $1.32 Million	Skr-12.96 Million ≈ $-1.40 Million	-1.057x	--

About XSpray Pharma AB

ST:XSPRAY Sweden Biotechnology

Market Cap

$47.66 Million

Skr442.87 Million SEK

Market Cap Rank

#22177 Global

#413 in Sweden

Share Price

Skr9.34

Change (1 day)

-3.61%

52-Week Range

Skr9.28 - Skr63.40

All Time High

Skr258.00